{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-048377","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2026-07-16T11:36:19+00:00","discovered_at":"2026-07-16T11:40:00.295628+00:00","generated_at":"2026-07-16T11:40:07.483589+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Abbott Q2 adjusted EPS $1.31; raises FY2026 EPS guidance to $5.45-$5.60","bullets":["Q2 reported sales $12.6B (+13.0% reported, +4.8% comparable); GAAP EPS $0.53, adjusted EPS $1.31.","Full-year 2026 adjusted EPS guidance raised to $5.45-$5.60 from $5.38-$5.58; comparable sales growth reaffirmed at 6.5%-7.5%.","Medical Devices comparable sales +8.4%; Diabetes Care CGM comparable sales +9.5%.","Returned $2.1B to shareholders in Q2 via dividends and share repurchases."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-048377","json":"https://secwatch.observer/filing/0001628280-26-048377.json","markdown":"https://secwatch.observer/filing/0001628280-26-048377.md","text":"https://secwatch.observer/filing/0001628280-26-048377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/0001628280-26-048377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/abt-20260716.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-16T11:40:07.483589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}